In This Article:
Over the last 7 days, the United States market has risen by 7.1%, contributing to a 7.7% increase over the past year, with earnings growth anticipated at 14% per annum in the coming years. In this environment, identifying stocks that may be trading below their estimated fair value can offer potential opportunities for investors looking to capitalize on future growth prospects.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| MINISO Group Holding (NYSE:MNSO) | $17.62 | $34.66 | 49.2% |
| ConnectOne Bancorp (NasdaqGS:CNOB) | $22.82 | $45.42 | 49.8% |
| Lantheus Holdings (NasdaqGM:LNTH) | $102.70 | $203.75 | 49.6% |
| Trade Desk (NasdaqGM:TTD) | $54.40 | $106.42 | 48.9% |
| First Reliance Bancshares (OTCPK:FSRL) | $9.35 | $18.65 | 49.9% |
| Shift4 Payments (NYSE:FOUR) | $79.66 | $158.86 | 49.9% |
| Veracyte (NasdaqGM:VCYT) | $31.67 | $62.84 | 49.6% |
| BigCommerce Holdings (NasdaqGM:BIGC) | $5.27 | $10.36 | 49.1% |
| Verra Mobility (NasdaqCM:VRRM) | $21.99 | $43.04 | 48.9% |
| Roku (NasdaqGS:ROKU) | $68.14 | $135.48 | 49.7% |
Let's uncover some gems from our specialized screener.
BeiGene
Overview: BeiGene, Ltd. is an oncology company focused on discovering and developing cancer treatments across the United States, China, Europe, and internationally with a market cap of approximately $26.39 billion.
Operations: The company generates revenue primarily from its pharmaceutical products, totaling $3.81 billion.
Estimated Discount To Fair Value: 46.9%
BeiGene's stock is trading significantly below its estimated fair value, presenting a potential opportunity for investors focused on cash flow valuation. Despite reporting a net loss of US$644.79 million in 2024, the company has shown revenue growth and expects further increases to between US$4.9 billion and US$5.3 billion in 2025. Recent strategic alliances and product approvals, such as TEVIMBRA's approval for ESCC treatment, bolster its position in the oncology market.
-
Our growth report here indicates BeiGene may be poised for an improving outlook.
-
Take a closer look at BeiGene's balance sheet health here in our report.
Roku
Overview: Roku, Inc. operates a TV streaming platform both in the United States and internationally, with a market cap of approximately $9.59 billion.
Operations: Roku generates revenue through its Devices segment, which contributed $590.12 million, and its Platform segment, which brought in $3.52 billion.
Estimated Discount To Fair Value: 49.7%
Roku's stock trades at US$68.14, significantly below its estimated fair value of US$135.48, highlighting potential undervaluation based on cash flows. Despite recent net losses, Roku's earnings are forecast to grow substantially over the next three years with expectations of profitability, surpassing average market growth rates. Recent product innovations and partnerships like Monster Jam enhance its platform offerings, potentially strengthening future cash flow prospects as it expands globally in streaming and device markets.